Grufity logo
Grufity logo
MBIO

MBIO - Mustang Bio Inc Stock Price, Fair Value and News

$0.68-0.06 (-8.11%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

48/100

MBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

MBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

MBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MBIO Price Action

Last 30 days

14.8%

Last 90 days

-21.3%

Trailing 12 Months

-40.2%

MBIO RSI Chart

MBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MBIO Valuation

Market Cap

5.0M

Price/Earnings (Trailing)

-1.83

Price/Sales (Trailing)

10.14

EV/EBITDA

5.98

Price/Free Cashflow

-1.02

MBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

MBIO Fundamentals

MBIO Revenue

Revenue (TTM)

491.0K

Rev. Growth (Yr)

3%

Rev. Growth (Qtr)

-21.97%

MBIO Earnings

Earnings (TTM)

-2.7M

Earnings Growth (Yr)

-524.18%

Earnings Growth (Qtr)

-77.51%

MBIO Profitability

EBT Margin

-391.24%

Return on Equity

-31.68%

Return on Assets

-16.42%

Free Cashflow Yield

-98.05%

MBIO Investor Care

Shares Dilution (1Y)

135.23%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026491.0K---
2025526.0K-368.0K453.0K
2024804.3K691.5K578.8K466.0K
20231.8M2.1M1.6M917.0K
2022367.0K310.0K894.0K1.4M
2021579.0K522.0K435.0K-
20201.4M1.1M885.0K708.0K
2019813.5K1.1M1.5M1.3M
2018560.5K563.3K566.2K569.0K
2017138.1K260.3K382.4K504.5K
2016---16.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Mustang Bio Inc

MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
 CEO
 WEBSITEmustangbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES113

Mustang Bio Inc Frequently Asked Questions

MBIO is the stock ticker symbol of Mustang Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Mustang Bio Inc is 4.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, MBIO's PE ratio (Price to Earnings) is -1.83 and Price to Sales (PS) ratio is 10.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBIO PE ratio will change depending on the future growth rate expectations of investors.